As we approach summer and vacations (at least for some of us in the office and most industry people here in Sweden), we wanted to take a moment to look back at the first half of the year. Here are some highlights of the year so far:
Simsen Diagnostics is announcing a new exciting collaboration with Orion Corporation, a Finnish pharmaceutical company, during a First-in-Human Phase I study to evaluate Orion’s drug candidate, ODM-212.
Simsen Diagnostics announces having received a Vinnova grant through the strategic innovation program Swelife to strengthen Life Science in Sweden and improve public health.